In the Spotlight: Emad Al Muti.
Get to know our analyst team one at a time in our new exclusive interviews
Emad Al Muti is one of our disease analysts working in our New York office. He’s been a part of the team since 2013 and has a duel background in both the scientific and business aspects of the pharmaceutical industry. We’ve put Emad “In the Spotlight” so you can find out more about what gets him excited about the pharma space and what he really does here at Datamonitor Healthcare…
What is your background?
After I finished my Bachelors in Pharmacy, I did a PHD in Pharmaceutical Sciences in the UK. When I moved to the US I pursued something that I’ve always wanted to do which is increase my knowledge about the business and management side of the pharmaceutical industry. That’s when I did my Masters in Pharmaceutical Management.
What is your role here at Datamonitor Healthcare?
I’m part of the diseases team within Datamonitor Healthcare and my work has predominately been working on specific disease areas since I joined. Mainly I’ve covered oncology, specifically the haematological cancers, and during the past year I’ve been helping to build our bacterial infectious diseases content
Within these areas, what has been your most interesting research project?
I think I would have to go to the bacterial infectious diseases area as this is very interesting as it’s been rather dormant, industry-wise, in the past decade or so. However, we’re seeing a lot of increased traction from government and regulatory agencies as we’re seeing more and more evolution of bacterial resistance.
Therefore this has been a really interesting project where I’ve been helping to build up our content and tackling some of the major types of bacterial infections that would be important for our clients to learn about.
What do you like most about working at Datamonitor Healthcare?
Multiple aspects really. In terms of the work itself, I think being able to combine the scientific analysis with a commercial view-point of the market is something very important for me and it allows me to give a better idea of the market in total to our clients.
As an analyst within the team, there is a high level of calibre of people that I’m working with. Everybody within the team comes from a very strong background and I think we’re fortunate to have such a team at Datamonitor Healthcare.
Why do you think our customers like Datamonitor Healthcare?
I think multiple things. Initially being that third party provider gives us the privilege of providing our clients with an unbiased opinion about the market. Something I’ve also noticed from my own interaction with clients is that they like the level of robustness in our research, whether it’s primary of secondary research, we try to get the information from as many sources as possible.
In addition, they like that we try as much as possible to be completely transparent and fully explain all of the sources of information that we adopt in our analysis.
What do you think your greatest achievement has been since working at Datamonitor Healthcare?
I think one thing that we’re trying very eagerly to do, and something I’m proud to be taking part in, is increasing the interaction between the analysts team and our clients. Myself and another analyst within the US have been heavily interacting with clients during the past year, for example doing site visits and client calls where we present our content and try to make it as easy as possible for our clients to access it and understand our research.
What are you most excited about this year in the pharmaceutical market?
I think within the blood cancer markets we have a lot of drugs that are coming up that have the ability to reinforce the treatment paradigms within the market.
Within the bacterial infectious disease market, as I mentioned previously, this is one area that’s evolving so fast that I think it’ll be very interesting to see how big pharma goes back to taking another dip into this market.
Outside work, what do you enjoy doing?
By nature I love travelling, so whenever I have the chance me and my family are always on the road exploring new places. Being in the US gives us an amazing chance just to visit different states and see different environments and cultures.
A big thank you to Emad for taking the time to talk to us!
- If you’d like to keep up to date with what Emad is up to this year you can follow him on twitter by clicking here.
- You can also read his full bio here.
If you’re interested in seeing more of what Emad does at Datamonitor Healthcare please download some of our free pieces of content below:
- Webinar: Recent Trends in the Treatment of Community-Acquired Pneumonia
- Infographic: Community-Acquired Pneumonia Treatment Trends
- White Paper: ASH 2014 Conference Review